- Home
- HOWL vs IKNA Comparison
HOWL vs IKNA Comparison
Compare HOWL & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- IKNA
- Stock Information
- Founded
- HOWL 2017
- IKNA 2016
- Country
- HOWL United States
- IKNA United States
- Employees
- HOWL N/A
- IKNA N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- IKNA Health Care
- Exchange
- HOWL Nasdaq
- IKNA Nasdaq
- Market Cap
- HOWL 53.4M
- IKNA 63.7M
- IPO Year
- HOWL 2021
- IKNA 2021
- Fundamental
- Price
- HOWL $1.25
- IKNA $1.36
- Analyst Decision
- HOWL Strong Buy
- IKNA Strong Buy
- Analyst Count
- HOWL 3
- IKNA 1
- Target Price
- HOWL $8.33
- IKNA $4.00
- AVG Volume (30 Days)
- HOWL 549.7K
- IKNA 60.0K
- Earning Date
- HOWL 08-07-2025
- IKNA 08-07-2025
- Dividend Yield
- HOWL N/A
- IKNA N/A
- EPS Growth
- HOWL N/A
- IKNA N/A
- EPS
- HOWL N/A
- IKNA N/A
- Revenue
- HOWL $1,143,000.00
- IKNA N/A
- Revenue This Year
- HOWL N/A
- IKNA N/A
- Revenue Next Year
- HOWL N/A
- IKNA N/A
- P/E Ratio
- HOWL N/A
- IKNA N/A
- Revenue Growth
- HOWL N/A
- IKNA N/A
- 52 Week Low
- HOWL $0.60
- IKNA $0.97
- 52 Week High
- HOWL $4.18
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- HOWL 45.36
- IKNA 53.81
- Support Level
- HOWL $1.03
- IKNA $1.31
- Resistance Level
- HOWL $1.10
- IKNA $1.42
- Average True Range (ATR)
- HOWL 0.07
- IKNA 0.05
- MACD
- HOWL -0.02
- IKNA -0.00
- Stochastic Oscillator
- HOWL 22.81
- IKNA 45.45
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.